[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.197.114. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
The Cutting Edge
November 2003

Topical Tacrolimus Ointment Is an Effective Therapy for Hailey-Hailey Disease

Author Affiliations
 

GEORGE J.HRUZAMDDEE ANNAGLASERMDELAINESIEGFRIEDMD

Arch Dermatol. 2003;139(11):1401-1402. doi:10.1001/archderm.139.11.1401
REPORT OF A CASE

A 67-year-old man with a 10-year history of flexural blistering eruptions also affecting 3 of his brothers was first evaluated in 1987. The patient presented with vesicles, erosions, and erythema in the intertriginous areas but also as multiple truncal plaques (Figure 1). Biopsy specimens showed intraepidermal clefts of varying sizes both suprabasally and higher in the epidermis, as well as the characteristic incomplete acantholysis in large parts of the epidermis, giving it the appearance of a "dilapidated brick wall" (Figure 2). The findings of a direct immunofluorescence evaluation were negative, which is consistent with a diagnosis of Hailey-Hailey disease (or chronic benign familial pemphigus).

Figure 1.
Hailey-Hailey disease with truncal lesions before treatment with 0.1% tacrolimus ointment.

Hailey-Hailey disease with truncal lesions before treatment with 0.1% tacrolimus ointment.

Figure 2.
A cleft is present within the epidermis, and the epithelium beneath the cleft shows partial acantholysis (hematoxylin-eosin, original magnification × 50).

A cleft is present within the epidermis, and the epithelium beneath the cleft shows partial acantholysis (hematoxylin-eosin, original magnification × 50).

A daily application of an ointment of betamethasone—a potent corticosteroid ointment—and clioquinol for 3 months gave no improvement in the condition. Similarly, neither topically applied clobetasol nor systemic antibiotics directed against Staphylococcus aureus had any disease-modifying effect. Then, 100 mg of dapsone daily and later 100 to 150 mg of azathioprine daily were administered successively for 3 months without significant beneficial effect. Oral daily treatment with 5 mg/kg of cyclosporine for 6 months reduced the activity of the disease, but this treatment was stopped owing to severe headache. Finally, 1% cyclosporine cream applied twice daily for 3 months did not result in healing. Because of the disseminated distribution of the lesions, carbon dioxide laser treatment was not considered an appropriate therapeutic option.

THERAPEUTIC CHALLENGE

As multiple therapies were either ineffective or associated with unacceptable side effects, topical therapy with 0.1% tacrolimus ointment (Protopic; Fujisawa Ireland LTD, Killorglin, Ireland) was initiated in April 2000.

SOLUTION

The patient was offered treatment with 0.1% tacrolimus ointment applied once daily to the affected areas. Clearance of the cutaneous lesions was observed within 1 month (Figure 3). A total amount of 30 g of tacrolimus ointment was needed to induce remission. Since then, the disease has been controlled by intermittent applications of tacrolimus ointment once daily for 2 to 3 weeks, without symptoms or signs of local or systemic toxicity. Routine blood test results and blood pressure measurements were within normal ranges. Blood levels of tacrolimus were not estimated during therapy. Interrupting tacrolimus ointment therapy resulted in gradual recurrence of vesicobullous lesions, but resuming tacrolimus treatment was associated with the disappearance of lesions within a few weeks.

Figure 3.
Disappearence of Hailey-Hailey truncal lesions after treatment with 0.1% tacrolimus ointment.

Disappearence of Hailey-Hailey truncal lesions after treatment with 0.1% tacrolimus ointment.

COMMENT

Hailey-Hailey disease is often difficult to treat. Therapeutic options include antibiotics to control secondary bacterial and viral infections. Immunomodulating therapy with corticosteroids,1 systemic and topical cyclosporine,2,3 oral retinoid,4 and the topical vitamin D analogue tacalcitol5 have been associated with reduced disease activity. This indicates that an inflammatory response is involved in the pathogenesis of the disease, which prompted us to evaluate the efficacy of 1% topical tacrolimus ointment (Protopic). What provokes the breakdown of the desmosome-keratin tonofilament complexes resulting in acantholytic keratinocytes is unknown. Tacrolimus, like cyclosporine, targets a calcium-activated phosphatase called calcineurin, thereby blocking the expression of several cytokines (interleukin [IL] 2, IL-3, IL-4, IL-5, granulocyte-monocyte colony-stimulating factor, and tumor necrosis factor α).6 It is suggested that the mechanism of action of topically applied tacrolimus ointment in Hailey-Hailey disease must be related in some way to the immunomodulating effect of the compound. Further studies are needed to define its mode of action at the molecular level.

During therapy with tacrolimus we could not detect symptoms or signs of systemic toxicity. However, we suggest that patients treated with tacrolimus ointment for Hailey-Hailey disease have a blood test to ensure that the concentration of tacrolimus is below the levels associated with immunosuppression.

Article
Submissions

Clinicians, local and regional societies, residents, and fellows are invited to submit cases of challenges in management and therapeutics to this section. Cases should follow the established pattern. Submit 4 double-spaced copies of the manuscript with right margins nonjustified and 4 sets of the illustrations. Photomicrographs and illustrations must be clear and submitted as positive color transparencies (35-mm slides) or black-and-white prints. Do not submit color prints unless accompanied by original transparencies. Material should be accompanied by the required copyright transfer statement, as noted in "Instructions for Authors." Material for this section should be submitted to George J. Hruza, MD, Laser and Dermatologic Surgery Center Inc, 14377 Woodlake Dr, Suite 111, St Louis, MO 63017.

Back to top
Article Information

Corresponding author: Carsten Sand, MD, DMSc, Department of Dermatology, D92, University of Copenhagen, Bispebjerg Hospital, Bispebjerg Bakke 23, 2400 Copenhagen, Denmark (e-mail: csp01@bbh.hosp.dk).

Accepted for publication April 17, 2003.

The authors have no relevant financial interest in this article.

References
1.
Burge  SM Hailey-Hailey disease: the clinical features, response to treatment and prognosis. Br J Dermatol. 1992;126275- 282
PubMedArticle
2.
Berth-Jones  JSmith  SGGraham-Brown  RA Benign familiar chronic pemphigus (Hailey-Hailey disease) responds to cyclosporine. Clin Exp Dermatol. 1995;2070- 72
PubMedArticle
3.
Jitsukawa  KRing  JWeyer  UKimming  WRadloff  H Topical cyclosporine in chronic benign familial pemphigus (Hailey-Hailey disease). J Am Acad Dermatol. 1992;27625- 626
PubMedArticle
4.
Hunt  MJSalisbury  ELPainter  DMLee  S Vesiculobullous Hailey-Hailey disease: successful treatment with oral retinoids. Australas J Dermatol. 1996;37196- 198
PubMedArticle
5.
Aoki  THashimoto  HKoseki  SHozumi  YKondo  S 1alpha, 24-dihydroxyvitamin D3 (tacalcitol) is effective against Hailey-Hailey disease both in vivo and in vitro. Br J Dermatol. 1998;139897- 901
PubMedArticle
6.
Nghiem  PPearson  GLangley  RG Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol. 2002;46228- 241
PubMedArticle
×